A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
Yap T, Papadopoulos K, LoRusso P, Wong D, Hu-Lieskovan S, Holz J. A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy. Journal Of Clinical Oncology 2019, 37: tps2652-tps2652. DOI: 10.1200/jco.2019.37.15_suppl.tps2652.Peer-Reviewed Original ResearchSafety Review CommitteePD-L1Dose escalationLAG-3PD-1/PD-L1 checkpoint inhibitorsPD-1/PD-L1 therapyPD-1/PD-L1 treatmentTranslational studiesSolid tumorsPD-1/PD-L1Immunotherapy-related adverse effectsPD-L1 checkpoint inhibitorsBispecific antibodiesLymphocyte activation gene-3PD-1 mAbPD-L1 treatmentPhase 2 dosePD-L1 therapyLAG-3 expressionMinority of patientsAnti-tumor responseSuperior anti-tumor efficacyEarly clinical trialsRemarkable anti-tumor activityHuman phase I